AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Thorn GroupLtd

1.165

+0.000

Volume:- -

Turnover:- -

Market Cap:40.50M

PE:3.99

High:1.165

Open:1.165

Low:1.165

Close:1.165

Loading ...

Overview Company News Filings

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Body Vision Medical Receives Regulatory Approval for LungVision® in Australia, Expanding Access to AI-Powered Advanced Imaging for Lung Cancer Diagnosis

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

1 big reason to buy CSL shares now

Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Junshi Biosciences Gets Nod to Market Toripalimab in Australia

MT Newswires Live

Guess which ASX 200 stock is jumping to record high on big European news

AirPods approved as hearings aids with Therapeutic Goods Administration tick

Sydney Morning Herald

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical

This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Why did this ASX biotech stock explode 52% higher on Monday?

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TGA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TGA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TGA.AU\",,,,,undefined,":{"symbol":"TGA.AU","market":"AU","secType":"STK","nameCN":"Thorn GroupLtd","latestPrice":1.165,"timestamp":1746165600000,"preClose":1.165,"halted":0,"volume":0,"delay":0,"nameEN":"Thorn GroupLtd","floatShares":10555948,"shares":34764019,"eps":0.291847,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-02 16:00:00 AEST","open":1.165,"high":1.165,"low":1.165,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.291847,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.165,"dividendRate":0.085837,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TGA.AU\",,,,,undefined,":{"symbol":"TGA.AU","floatShares":10555948,"roa":"2.77%","roe":"-5.00%","lyrEps":0.073491,"shares":34764019,"dividePrice":0.1,"high":1.165,"amplitude":0,"preClose":1.165,"low":1.165,"week52Low":1.165,"pbRate":"0.95","psRate":"2.87","week52High":1.165,"institutionHeld":0,"latestPrice":1.165,"eps":0.291847,"divideRate":0.085837,"volume":0,"delay":0,"ttmEps":0.291847,"open":1.165,"prevYearClose":1.165,"prevWeekClose":1.165,"prevMonthClose":1.165,"prevQuarterClose":1.165,"fiveDayClose":1.165,"twentyDayClose":1.165,"sixtyDayClose":1.165},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TGA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527412783","title":"SECuRE trial update: First patient treated in the Phase II Cohort Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412783","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412783?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:02","pubTimestamp":1744722120,"startTime":"0","endTime":"0","summary":"The first of the planned 24 participants in the Cohort Expansion Phase  of theSECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee  after the successful completion of the Dose Escalation Phase to commence enrollment for the Cohort Expansion Phase at the 8 GBq dose level, with an increase of the number of cycles from up to 4 to up to 6.This participant will be treated with the combination of 8GBq of 67Cu-SAR-bisPSMA with enzalutamide , as per the recent protocol amendment to include a subset of participants in the Cohort Expansion Phase to receive this combination.The recently amended SECuRE trial protocol will also focus on the evaluation of metastatic castration-resistant prostate cancer  participants in the pre-chemotherapy setting. This aligns with Clarity's strategy of bringing 67Cu-SAR-bisPSMA to earlier stages of the disease and is based on its promising safety and efficacy data, esp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/secure-trial-first-patient-treated-130200983.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/secure-trial-first-patient-treated-130200983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7001","BK4084","SRC","BK4533","BK4588","BK4080","BK4135","PSA","BK4213","CU6.AU","SAR","BK4231","BK7096","SAR.AU","BK4585","BK4217","TGA","TGA.AU"],"gpt_icon":0},{"id":"2520842426","title":"Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2520842426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520842426?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:53","pubTimestamp":1742248380,"startTime":"0","endTime":"0","summary":"MELBOURNE,Australia andPORTO ALEGRE,Brazil, March 18, 2025  -- Telix Pharmaceuticals Limited  today announces that the Brazilian Health Regulatory Agency  has approved Illuccix  the Company’s lead prostate cancer imaging agent. Illuccix is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil.Illuccix, after radiolabeling with 68Ga, is a radioactive diagnostic agent indicated for positron emission tomography  of prostate-specific membrane antigen  positive lesions in men with prostate cancer:. With suspected metastasis who are candidates for definitive initial therapy treatment, and. With suspected recurrence based on an elevated specific antigen  level in the serum.PSMA-PET is a diagnostic technology demonstrated to detect advanced prostate cancer. ANVISA becomes the latest regulatory body worldwide to approve Illuccix3, which is already commercially available in Australia, Canada, New Zealand and the United States, and has recently b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illuccix-approved-prostate-cancer-imaging-215300352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["DCP","SEC.AU","TGA","BK4139","BK7067","TLX.AU","XKO.AU","BK4528","BK4588","XAO.AU","BK7001","BK4526","BK7039","BK4543","BK4233","BK7047","BK4192","BK4585","BK4205","PSA","ASX","UK","BK4217","TLX","BK4141","BK4084","BK4213","PET","XJO.AU","TGA.AU","BK4533","BK4144","EEA","ASX.AU","PET.AU"],"gpt_icon":0},{"id":"2518674345","title":"Body Vision Medical Receives Regulatory Approval for LungVision® in Australia, Expanding Access to AI-Powered Advanced Imaging for Lung Cancer Diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2518674345","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518674345?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:05","pubTimestamp":1741694700,"startTime":"0","endTime":"0","summary":"Lung cancer remains the leading cause of cancer-related deaths in Australia, with an estimated 14,500 new cases diagnosed annually. With the Australian Government Department of Health and Aged Care rolling out the National Lung Cancer Screening Program  to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules.\"This approval represents a major step forward in our global mission to transform lung cancer care,\" said Matt Baker, CEO at Body Vision Medical. \"We are thrilled to partner with ParagonCare to make LungVision available in Australia and New Zealand, where the need for accurate, early-stage lung cancer diagnosis is more critical than ever.\". \"We are excited to welcome Body Vision Medical's technology to our portfolio, as it strengthens our commitment to advancing augmented lung and respiratory medicine through cutting-edge AI,\" said Tiffany Chiew, General Manager Capital and Service at Pa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/body-vision-medical-receives-regulatory-120500228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/body-vision-medical-receives-regulatory-120500228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XAO.AU","BK4157","PGC.AU","IE00B19Z4B17.USD","TGA","XKO.AU","BK7001","XJO.AU","IE0031619046.USD","BK4213","TGA.AU","AEIS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK7103"],"gpt_icon":0},{"id":"2517261912","title":"SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517261912","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517261912?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:44","pubTimestamp":1741182240,"startTime":"0","endTime":"0","summary":"Safety Review Committee  meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase  of the SECuRE study.Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, theSRC confirmed expansion at 8 GBq dose level and recommended to increase the number of cycles from up to 4 to up to 6.Cohort 4 of the Dose Escalation Phase of theSECuRE trial, assessing multiple administrations of 67Cu-SAR-bisPSMA, is complete. Prostate-specific antigen  levels are continuing to drop in 3 participants,with reductions ≥80% observed in 3 cases so far. A complete response was achieved in a participant in cohort 4 following 2 doses of 12 GBq of 67Cu-SAR-bisPSMA to date, based on the Response Evaluation Criteria in Solid Tumors v1.1 .Across all cohorts, 68% of participants have shown reductions inPSA levels, despite the vast majority of the participants (77%) only receiving a single dose of 67Cu-SAR-bisPSMA. The majority of part","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/secure-trial-92-pre-chemo-134400223.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/secure-trial-92-pre-chemo-134400223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7001","SAR.AU","BK4585","DLT.AU","BK7095","PSA","BK4084","BK4533","BK4217","SAR","BK7084","RLT.AU","BK4213","BK7142","TGA","SRC","BK7096","ADT.AU","BK4192","BK4588","BK4231","BK4080","ADT","TGA.AU","BK4165","BK4135","CU6.AU"],"gpt_icon":0},{"id":"2512100248","title":"Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2512100248","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512100248?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:09","pubTimestamp":1739974140,"startTime":"0","endTime":"0","summary":"This milestone builds on Clarity's earlier receipt of 2 FTDs for the diagnostic 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1], as well as patients with biochemical recurrence  of prostate cancer following definitive therapy[2], with 2 Phase III registration trials underway . These 3 FTDs demonstrate the quality of the data generated to date on the 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA products in addressing serious unmet needs in prostate cancer. The FTDs will enable Clarity to accelerate the development of its comprehensive program with the optimised SAR-bisPSMA agent to be used in patients with prostate cancer throughout the management of their cancer, from initial to late-stage disease, with an opportunity to completely change the entire treatment landscape for the large prostate cancer market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-receives-us-fda-fast-140900114.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-receives-us-fda-fast-140900114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["SAR","BK4213","BK4567","FAST","CU6.AU","BK4217","TGA","BK4084","PSA","BK4588","IE00BFXG0V08.USD","BK4104","BK7001","BCR","IE00B5TLWC47.USD","BK4585","BK4533","TGA.AU","SAR.AU","BK4135","IE00BYQQ9H92.USD","BK7096"],"gpt_icon":0},{"id":"2507084522","title":"1 big reason to buy CSL shares now","url":"https://stock-news.laohu8.com/highlight/detail?id=2507084522","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507084522?lang=en_us&edition=fundamental","pubTime":"2025-01-29 06:24","pubTimestamp":1738103061,"startTime":"0","endTime":"0","summary":"If you have been thinking about buying CSL Ltd  shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares. Why are CSL shares a buy?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/29/1-big-reason-to-buy-csl-shares-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1791807156.HKD","SG9999004303.SGD","BK4086","LU1169589451.USD","LU1668664300.SGD","LU2237443465.HKD","BK7511","BK4156","TGA.AU","HAE","BK7001","LU0106831901.USD","IE00BSNM7G36.USD","LU2237438978.USD","LU2237443549.SGD","LU1169590202.USD","SGXZ23171101.USD","IE00B64QTZ34.USD","IE00BLDYK493.USD","LU2237443895.HKD","CSL","BK4127","BK4213","IE0002270589.USD","IE0034235188.USD","LU2237443622.USD","LU0728928796.USD","BK4533","IE0004091025.USD","IE00B19Z3B42.SGD","LU0205193047.USD","TGA","LU2237443382.USD","BK7501","BK4588","BK7067","LU0205194284.USD","LU0012050646.USD","BK4585","CSL.AU","LU2237443978.SGD","IE0004086264.USD","IE00BFXG1179.USD","BK4198","BK4516","LU0106261612.USD","BK7508","BK4550","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2506224519","title":"Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2506224519","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506224519?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:04","pubTimestamp":1738073040,"startTime":"0","endTime":"0","summary":"Two abstracts on Clarity's diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium  2025.An abstract on the COBRA study has also been selected for presentation at the American Urological Association  Annual Meeting 2025.In a subset of participants in the COBRA study who underwent follow-up SOC PSMA PET, 70% of participants had a positive scan on same-day imaging and 90% on next-day imaging using 64Cu-SAR-bisPSMA, compared to 60% of participants using SOC PSMA PET where only same-day imaging is possible. The number of lesions across all participants  identified by 64Cu-SAR-bisPSMA was also higher  than that detected by SOC PET agents . Results indicate that 64Cu-SAR-bisPSMA is able to identify lesions from 29 days to more than 6 months earlier than SOC PSMA agents. Across all participants in the study, histopathology confirmed the presence of prostate cancer in lesions iden","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0348723411.USD","BK4192","BK4213","SAR","LU1861215975.USD","LU1861220033.SGD","PET","SOC.AU","CU6.AU","BK7047","LU0124384867.USD","LU1720051108.HKD","AUA.AU","LU0724618433.USD","TGA","LU1720051017.SGD","IE00BZ199S13.USD","BK4512","BK4588","BK7001","BK7003","SOC","BCR","LU1861219969.SGD","LU1861214812.USD","BK4585","LU1854104046.USD","LU1978683503.SGD","LU1548497426.USD","TGA.AU","BK4141","LU1854103824.USD","SAR.AU","LU2360107325.USD","BK7061","ON","LU2298322129.HKD","LU2357305700.SGD","BK4135","PET.AU","IE00BD6J9T35.USD","BK7096"],"gpt_icon":0},{"id":"2505865344","title":"Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505865344","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505865344?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:02","pubTimestamp":1737727320,"startTime":"0","endTime":"0","summary":"This milestone builds on Clarity's earlier receipt of an FTD for 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1]. These 2 FTDs enable the Company to accelerate the development of its comprehensive diagnostic program with this product.The FDA's FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For 64Cu-SAR-bisPSMA, it provides a number of product development advantages. The designation paves the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4135","BK4567","SOC","SAR","BK4213","BK7096","BK7061","BK4104","BK4585","BK4588","SOC.AU","IE00B5TLWC47.USD","BK7047","BK7001","BCR","FAST","SAR.AU","PET.AU","IE00BFXG0V08.USD","TGA","PET","BK4192","IE00BYQQ9H92.USD","CU6.AU","TGA.AU"],"gpt_icon":0},{"id":"2505742891","title":"Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2505742891","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505742891?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327G. “R327G has made significant progress over the last year, confirming its safety profile and demonstrating impressive efficacy as a topical gel formulation, especially considering the high degree of bacterial resistance present in many of the patients being treated in this Phase II trial,” said James Graham, CEO of Recce Pharmaceuticals. “We look forward to the full dataset, which we expect will further support R327G's progress toward regulatory evaluation.”Thus far, no serious adverse events have been reported, and all patients dosed with R327G have achieved positive outcomes. The full set of data will be reviewed by the Data Safety Monitoring Board with complete results expected to be announced in Q1 2025. Recce is expected to initiate a Phase III study of R327G in Australia in H1 2025 that will serve as a registrational trial for the U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recce-pharmaceuticals-doses-patients-phase-130000740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4017","AMR","BK7001","XJO.AU","LU1223083913.SGD","GAIN","BK4585","LU1223082519.USD","LU0368265764.SGD","LU1223082196.USD","XKO.AU","TGA","BK7096","LU0788108826.HKD","USA","AU","LU0496367417.USD","BK4570","LU0498741890.SGD","BK4588","BK4522","LU0055631609.USD","LU0498741114.HKD","BK4533","BK4135","LU0724618789.USD","BK4213","BK4006","RCE.AU","XAO.AU","TGA.AU"],"gpt_icon":0},{"id":"2504642193","title":"Junshi Biosciences Gets Nod to Market Toripalimab in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2504642193","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504642193?lang=en_us&edition=fundamental","pubTime":"2025-01-20 15:02","pubTimestamp":1737356523,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  obtained approval from Australia's Therapeutic Goods Administration  to market the drug toripalimab, according to a Hong Kong Stock Exchange disclosure on Jan. 17.The TGA approved the new chemical entity application for toripalimab in combination with cisplatin and gemcitabine as a treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma or NPC.Toripalimab was also approved as a single agent to treat adults with unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy, the filing said.The pharmaceutical company's Shanghai shares rose more than 1% and Hong Kong shares climbed less than 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","01877","XAO.AU","XKO.AU","BK1515","TGA","BK0239","BK7001","BK4213","688180","TGA.AU","XJO.AU"],"gpt_icon":0},{"id":"2504597844","title":"Guess which ASX 200 stock is jumping to record high on big European news","url":"https://stock-news.laohu8.com/highlight/detail?id=2504597844","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504597844?lang=en_us&edition=fundamental","pubTime":"2025-01-17 07:18","pubTimestamp":1737069517,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  shares are ending the week on a positive note. In morning trade on Friday, the ASX 200 healthcare stock is up 4.5% to a record high of $27.00. Why is this ASX 200 healthcare stock racing higher?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/17/guess-which-asx-200-stock-is-jumping-to-record-high-on-big-european-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4208","TGA","LU1894683264.USD","BK4585","TLX.AU","RMS.AU","EEA","BK4588","PET","BCR","BK7067","BK4213","BK7104","MAA","BK4215","TGA.AU","BK4192","CMS","LU2637428348.USD","PET.AU","BK7001","LU2346227817.USD","BK4144","BK7506","DCP","BK7047","LU1894683348.USD"],"gpt_icon":0},{"id":"2493925789","title":"AirPods approved as hearings aids with Therapeutic Goods Administration tick","url":"https://stock-news.laohu8.com/highlight/detail?id=2493925789","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493925789?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:47","pubTimestamp":1734936475,"startTime":"0","endTime":"0","summary":"One of the most common pieces of tech has been given a massive new dimension with the approval of life-changing technology in Australia.","market":"us","thumbnail":"https://images.perthnow.com.au/publication/C-17177437/c20b0f4aa81fae0b6d281e66362eea68da587aa4-16x9-x0y0w2048h1152.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-17177437/c20b0f4aa81fae0b6d281e66362eea68da587aa4-16x9-x0y0w2048h1152.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/technology/airpods-approved-as-hearings-aids-with-therapeutic-goods-administration-tick-c-17177437","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/technology/airpods-approved-as-hearings-aids-with-therapeutic-goods-administration-tick-c-17177437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["XKO.AU","BK4213","TGA","BK7001","TGA.AU","XJO.AU","XAO.AU"],"gpt_icon":0},{"id":"2492189536","title":"Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2492189536","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492189536?lang=en_us&edition=fundamental","pubTime":"2024-12-18 22:03","pubTimestamp":1734530580,"startTime":"0","endTime":"0","summary":"The product, termed SAR-bisFAP, has shown strong tumour targeting, retention and pharmacokinetic data to date in pre-clinical models.FAP is expressed widely across a range of malignancies, opening a very large pan-cancer opportunity for both imaging and treatment of various cancers.Clarity continues to develop a range of novel products through its Discovery Program with strong patent protection aimed at improving treatment outcomes in indications with high unmet needs.FAP is expressed on cancer associated fibroblasts , a particular cell type found in the tumour microenvironment . CAFs are found in a broad range of cancers , but only minimally in normal tissue, making FAP a promising pan-cancer target for both imaging and treatment of cancers1. CAFs form part of the environment surrounding the cancer cells, and they can promote cancer growth and the spread of the tumour throughout the body2. Targeting the tumour stroma is an alternative way to treat cancer whereby the architecture of th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9fp57r7drKSqvSvMhd0Xgw--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9fp57r7drKSqvSvMhd0Xgw--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-expands-pipeline-novel-optimised-140300523.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-expands-pipeline-novel-optimised-140300523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7001","CU6.AU","BK7096","BK4213","TGA.AU","TGA"],"gpt_icon":0},{"id":"2489812271","title":"This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2489812271","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489812271?lang=en_us&edition=fundamental","pubTime":"2024-12-05 07:25","pubTimestamp":1733354745,"startTime":"0","endTime":"0","summary":"ASX healthcare stock Paradigm Biopharmaceuticals Ltd  has been on a strong run in the past month, soaring 160%.But the drug development company has requested a pause in the trading of its shares before the open on Thursday.Before the halt, Paradigm shares finished the session on Wednesday at 58 cents. Let's take a closer look.Paradigm requested its shares be put on ice starting Thursday, saying that it intends to update the market on a capital raising in the coming days.The pause in trading is expected to remain in place until next Monday, December 9, but trading will resume earlier if the ASX healthcare stock provides an update beforehand.Investors have flooded into Paradigm shares in recent weeks, with prices exploding on optimism surrounding its flagship drug candidate, Zilosul.Last week, the company confirmed it had not received feedback from the US Food and Drug Administration  regarding its revised Phase 3 clinical trial protocol for Zilosul.Meanwhile, Paradigm is also awaiting a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/this-asx-healthcare-stock-is-up-160-in-a-month-heres-why-its-just-entered-a-trading-halt/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PAR.AU","TGA.AU","BK7508","BK7067","BK7001","BK4213","IND.AU","TGA","BK7095"],"gpt_icon":0},{"id":"2486339823","title":"First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2486339823","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486339823?lang=en_us&edition=fundamental","pubTime":"2024-11-28 17:22","pubTimestamp":1732785720,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ --Telix Pharmaceuticals Limited  and Grand Pharmaceutical Group Limited  today announce that afirst patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography  imaging of clear cell renal cell carcinoma . The patient was successfully dosed and imaged at Beijing Cancer Hospital in Beijing, China.Dr David N. Cade, Chief Medical Officer at Telix said, \"Dosing and imaging a first patient in the ZIRCON-CP trial is a significant milestone for Telix and our partner Grand Pharma. We would like to thank Professor Peng Du and his team, as well as the patients who will contribute to this important trial, helping to advance TLX250-CDx towards regulatory filings in Greater China, where there is currently critical unmet medical need.\". As part of Telix's commitment to access to medicine, the Company continues to run an expanded access program  in the U.S.[4], named patient programs  in Europe, and a special acce","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uRsjF.FvOx.8TgpjnSsWgg--~B/aD0xNjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uRsjF.FvOx.8TgpjnSsWgg--~B/aD0xNjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/first-patient-dosed-phase-iii-092200081.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/first-patient-dosed-phase-iii-092200081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4141","XAO.AU","BK7047","ASX","PET.AU","III","TGA.AU","BK7001","TLX.AU","BK7039","PET","XKO.AU","BK4134","XJO.AU","ASX.AU","BK7067","CP","BK4016","BK4526","BK4588","SEC.AU","BK4192","LU1261432733.SGD","TGA","BK4139","BK4213","TLX","BK4585"],"gpt_icon":0},{"id":"2486736776","title":"Why did this ASX biotech stock explode 52% higher on Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486736776","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486736776?lang=en_us&edition=fundamental","pubTime":"2024-11-25 14:21","pubTimestamp":1732515686,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals Ltd  shares started the week with an almighty bang. The ASX biotech stock ended the session almost 42% higher at 46 cents. At one stage, the biopharmaceutical company's shares were up as much as 52% to a 52-week high of 49.5 cents. Why did this ASX biotech stock rocket?Investors were bidding the company's shares higher today despite there being no news out of it. Though, interestingly, the lack of news was arguably the trigger for this rampant buying, with investors deeming no news to be very good news. The buying was so strong that it even led to the Australian stock exchange operator giving the ASX biotech stock a speeding ticket. It said:  Is PAR aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?In response, the biotech said:  No, the Company is not aware of any information concerning it that has not been announced to the market which, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/25/why-did-this-asx-biotech-stock-explode-52-higher-on-monday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK4213","TGA","TGA.AU","XKO.AU","XJO.AU","PAR.AU","BK7001","BK7508","XAO.AU"],"gpt_icon":0},{"id":"2484938707","title":"Telix to Add FAP-Targeting Candidates to Theranostic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2484938707","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484938707?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:24","pubTimestamp":1731968640,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein , one of the most promising pan-cancer targets in nuclear medicine.Telix's development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers.FAP is a pan-cancer marker expressed in the tumour microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.Visit the Telix corporate website to view an interactive explainer on FAP: Attack on Stroma. Under an exclusive worldwide licence agreement with a German company controlled by Professor Roesch, SCV GmbH, and a concurrently-signed asset purchase agreement with German company Medianezia GmbH, which collectively hold the intellectual","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uRsjF.FvOx.8TgpjnSsWgg--~B/aD0xNjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uRsjF.FvOx.8TgpjnSsWgg--~B/aD0xNjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/telix-add-fap-targeting-candidates-222400602.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-add-fap-targeting-candidates-222400602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7001","BK7067","BK4526","ASX.AU","TGA","TLX","ASX","BK4141","SEC.AU","TGA.AU","BK4213","TLX.AU","XKO.AU","XAO.AU","BK7039","XJO.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TGA.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-12-13","symbol":"TGA.AU","reason":null,"defaultRemindTime":1702422000000,"announcedDate":"2023-12-11","type":"delisting","dateTimestamp":1702386000000},{"date":"2023-11-30","symbol":"TGA.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1701298800000,"name":null,"time":"","dateTimestamp":1701262800000,"actualEps":null},{"date":"2023-09-05","symbol":"TGA.AU","amount":0.45,"announcedDate":"2023-08-01","type":"dividend","market":"AU","newRecordDate":"2023-09-06","defaultRemindTime":1693872000000,"name":"Thorn GroupLtd","recordDate":"2023-09-22","payableDate":"2023-09-06","currency":"AUD","dateTimestamp":1693836000000,"payDate":"2023-09-22"},{"date":"2023-05-31","symbol":"TGA.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1685491200000,"name":null,"time":"","dateTimestamp":1685455200000,"actualEps":null},{"date":"2022-11-30","symbol":"TGA.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1669762800000,"name":null,"time":"","dateTimestamp":1669726800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TGA.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-10-16","recordDate":"2020-10-19","paymentDate":"2020-11-03","value":0.075,"currency":"AUD"},{"executeDate":"2021-07-02","recordDate":"2021-07-05","paymentDate":"2021-07-21","value":0.01,"currency":"AUD"},{"executeDate":"2022-01-24","recordDate":"2022-01-25","paymentDate":"2022-02-09","value":0.07,"currency":"AUD"},{"executeDate":"2022-07-06","recordDate":"2022-07-07","paymentDate":"2022-07-25","value":0.01,"currency":"AUD"},{"executeDate":"2022-08-24","recordDate":"2022-08-25","paymentDate":"2022-09-08","value":0.03,"currency":"AUD"}]}}